Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis

Journal of Dermatological Treatment

Volumn 22, Issue 6, 2011, Pages 359-365

  De Belilovsky, Clarence ^a   Roo Rodriguez, Elia ^b   Baudouin, Caroline ^c   Menu, Franck ^c   Chadoutaud, Bernard ^d   Msika, Philippe ^c  

^a INSTITUT ALFRED FOURNIER   (France)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c Innovation Research and Development Direction   (France)

^d ClinReal Online   (France)

Author keywords

Atopic dermatitis; Emollient; PPAR alpha agonist; Quality of life

Indexed keywords

CENEO; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; HYDROCORTISONE BUTYROPROPIONATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLANT EXTRACT; STELATOPIA; SUNFLOWER OLEODISTILLATE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; ATOPIC DERMATITIS; CHILD; CREAM; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; INFANT; INFANT DERMATITIS QUALITY OF LIFE AND DERMATITIS FAMILY IMPACT QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SUNFLOWER; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EMOLLIENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; INFANT; MALE; PPAR ALPHA; QUALITY OF LIFE; REFERENCE VALUES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 80855150740     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.499932     Document Type: Article

References (22)

1. Proksch E, Jensen JM, Elias PM. Skin lipids and epidermal differentiation in atopic dermatitis. Clin Dermatol. 2003;21: 134-144. (Pubitemid 36428984)
2. Elias P, Steinhoff M. 'Outside-to-inside' (and now back to 'outside') pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128:1067-1070. (Pubitemid 351543225)
3. Kurahashi R, Hatano Y, Katagiri K. IL-4 suppress the recovery of cutaneous permeability barrier function in vivo. J Invest Dermatol. 2008;128:1329-1331. (Pubitemid 351543188)
4. Consensus Conference Management of atopic dermatitis in children. Recommendations (short version). Eur J Dermatol. 2005;15:215-223.
5. Kao JS, Fluhr JW, Man MQ, Fowler AG, Hachem JP, Crumrine D, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456-464. (Pubitemid 36298433)
6. Eichenfield L, McCollum A, Msika P. The benefits of Sunflower Oleodistillate in pediatric dermatology. Pediatr Dermatol. 2009;26:669-675.
7. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008;25:606-612.
8. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants' Dermatitis Quality of Life Index. Br J Dermatol. 2001;144:104-110. (Pubitemid 32154600)
9. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: The Dermatitis Family Impact Questionnaire. Br J Dermatol. 1998;138:107-113. (Pubitemid 28077946)
10. Hanifin JM, Hebert AA, Mays SR, Paller AS, Sherertz EF, Wagner AM, et al. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res. 1998;59:227-233. (Pubitemid 28206661)
11. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321-324. (Pubitemid 27332923)
12. Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: A randomized controlled study. Dermatology. 2007;214: 61-67. (Pubitemid 46033003)
13. Boguniewicz M, Zeichner JA, Eichenfield LF, Hebert AA, Jarrat M, Lucky AW, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: A multicenter, randomized, vehicle-controlled study. J Pediatr. 2008;152:854-859.
14. Patrizi A, Capitanio B, Giacomini F, Sinagra JL, Raone B, Beradesca E. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol. 2008;19: 619-625.
15. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: Assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22:73-82.
16. Kuenzli S, Saurat JH. Peroxisome proliferator-Activated receptors in cutaneous biology. Br J Dermatol. 2003;149: 229-232.
17. Rivier M, Castiel I, Safonova I, Ailhaud G, Michel S. Peroxisome proliferator-Activated receptor-Alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol. 2000;114:681-687. (Pubitemid 30227000)
18. Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol. 2000;115:353-360.
19. Komuves LG, Hanley K, Man MQ, Elias PM, William ML, Feingold KR. Keratinocyte differentiation in hyperproliferative epidermis: Topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol. 2000;115: 361-367.
20. Staumont-Sallé D, Abboud G, Brénuchon C, Kanda A, Roumier T, Lavogiez C, et al. Peroxisome proliferatoractivated receptor a regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol. 2008; 121:962-968.
21. Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, et al. Murine atopic dermatitis responds to peroxisome proliferator-Activated receptors a and b/d (but not g) and liver X receptors activators. J Allergy Clin Immunol. 2010;125:160-169.
22. Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, et al. Peroxisome proliferator-Activated receptor-A contributes to the anti-inflammatory activity of glucocorticoids. Mol Pharmacol. 2008;73:323-337. (Pubitemid 351181185)